Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lorundrostat - Mineralys Therapeutics

Next Previous
Drug Profile

Lorundrostat - Mineralys Therapeutics

Alternative Names: MLS-101; MT-4129

Latest Information Update: 11 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Developer Mineralys Therapeutics; Mitsubishi Tanabe Pharma Corporation
  • Class Acetamides; Amides; Antihypertensives; Benzene derivatives; Cardiovascular therapies; Cyclohexylamines; Sleep disorder therapies; Small molecules; Triazines; Urologics
  • Mechanism of Action Cytochrome P-450 CYP11B2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hypertension
  • Phase II Renal failure; Sleep apnoea syndrome
  • No development reported Cardiovascular disorders

Most Recent Events

  • 05 Sep 2025 Mineralys Therapeutics announces intention to submit NDA to FDA for Hypertension in the fourth quarter of 2025 or the first quarter of 2026
  • 05 Sep 2025 Mineralys Therapeutics plans a pre-NDA meeting with the FDA in the fourth quarter of 2025
  • 30 Jun 2025 Adverse events and efficacy data from a phase II LAUNCH-HTN trial in Hypertension released by Mineralys Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top